ALXN News and Press, Alexion Pharmaceuticals Inc. From 08/22/19

A potential deal for Amgen (NASDAQ: AMGN ) to buy Alexion Pharmaceuticals (NASDAQ: ALXN ) “would be highly accretive,” Mizuho says. More news on: Amgen Inc., Alexion Pharmaceuticals, Inc., Merger & acquisition news, Stocks on the move, Healthcare stocks news, Read mor...

Background - why it's just another stock now At its peak in 2014-5, Gilead Sciences ( GILD ) had almost everything going for it. Its HCV drugs had the sales momentum and headlines. And a growing number of analysts were signing on to the argument I put forth in The Importance Of TAF To Gilea...

Introduction I've only had time to do three Q2 articles on biotechs, including Edwards ( EW ) in that category. In this article, I'll therefore present some comments on stocks which I have not written about in a few months or longer, as well a brief update on my largest biotech holding, Merc...

Achillion Pharmaceuticals ( ACHN ) had achieved a massive surge in stock price recently. It all started when it had reported positive data from a phase 1 study using its drug ACH-5228. This data was early, but investors were optimistic based on the initial findings of the impressive sustai...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Alexion Pharmaceuticals' (NASDAQ: ALXN ) Soliris (eculizumab) for the treatment of adult patients with relapsing anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spect...

- At 48 weeks, 98% of adult patients who are anti-aquaporin-4 (AQP4) antibody positive and were treated with SOLIRIS were relapse free compared to 63% receiving placebo - - Final European Commission decision anticipated in September 2019; SOLIRIS has the potential to be the first and o...

Alexion Pharmaceuticals, Inc. (ALXN) Q2 2019 Earnings Conference Call July 24, 2019 08:00 AM ET Company Participants Susan Altschuller - Vice President of Investor Relations Ludwig Hantson - Chief Executive Officer Paul Clancy - EVP and Chief Financial Officer John Orloff - EVP...

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2019 Q2 earnings Read more ...

Alexion Pharmaceuticals ( ALXN -2.4% ) Q2 results : Revenues: $1,203.3M (+15.1%); Soliris: $980.8M (+9.2%); Ultomiris: $54.2M; Strensiq: $141.3M (+12.9%); Kanuma: $26.2M (22.4%). More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read ...

Alexion Pharmaceuticals (NASDAQ: ALXN ): Q2 Non-GAAP EPS of $2.64 beats by $0.30 ; GAAP EPS of $2.04 beats by $0.28 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...